Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

120.09 -0.18 (-0.15%)

Streaming Delayed Price Updated: 2:58 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗

February 17, 2026

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

Glaukos (GKOS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

February 17, 2026

From Glaukos Corporation

Via Business Wire

Director Sells GKOS 15,000 Shares for $1.9 Million ↗

January 31, 2026

This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

January 28, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

January 20, 2026

From Glaukos Corporation

Via Business Wire

These stocks are moving in today's after hours session ↗

January 13, 2026

Via Chartmill

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

January 13, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

December 16, 2025

From Glaukos Corporation

Via Business Wire

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗

November 06, 2025

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off

Via The Motley Fool

Topics Regulatory Compliance

Glaukos Announces Participation in Upcoming Investor Conferences

November 03, 2025

From Glaukos Corporation

Via Business Wire

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday ↗

October 30, 2025

The company's recent past featured robust growth, and it anticipates continued rises into the near future.

Via The Motley Fool

Glaukos (GKOS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Glaukos (GKOS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

October 30, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 30, 2025

Via Benzinga

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 30, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2025

Via Benzinga

Why Glaukos Stock Jumped Over 20% After-Hours Today ↗

October 29, 2025

Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.

Via Stocktwits

What's going on in today's after hours session ↗

October 29, 2025

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Glaukos Corp (NYSE:GKOS) Soars on Strong Q3 2025 Earnings Beat and Robust 2026 Outlook ↗

October 29, 2025

Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 29, 2025

Via Benzinga

Glaukos Announces Third Quarter 2025 Financial Results

October 29, 2025

From Glaukos Corporation

Via Business Wire

Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.